Business
CollPlant Presents Its rhCollagen-based BioInks for 3D Bioprinting of Tissues and Organs at TERMIS Annual Meeting in Rhodes, Greece
REHOVOT, Israel, May 28, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced that Dr. Nadav Orr, the Company's
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":" REHOVOT, Israel, May 28, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative medicine company, today announced that Dr. Nadav Orr, the Company's Vice President for R&D, presented the utilization of CollPlant's recombinant human collagen (rhCollagen) in the field of 3D Bioprinting tissues and organs at the Annual Meeting of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) European Union Chapter in Rhodes, Greece on Monday, May 27, 2019. \nAt the session dedicated to bioartificial organs, Dr. Orr demonstrated the unique properties of CollPlant's BioInks which are formulated and optimized for 3D Bioprinting of tissues and organs. The presentation is titled, \"Recombinant Human Type I Collagen Compositions for 3D-Bioprinting of Tissues and Organs\".\n\"Our BioInk compositions are ideal for use in 3D Bioprinting and we believe they are superior to compositions formulated with other types of collagens. This superiority is a derivative of the unique properties of our rhCollagen, which is an ideal building block for scaffolds used in regenerative medicine,\" stated CollPlant CEO, Yehiel Tal. \"TERMIS is the most prominent organization in the field of tissue engineering and regenerative medicine globally, and we were pleased to present to, and meet with, the key players in this emerging field poised to transform healthcare.\"\nAbout TERMIS-EU 2019\nThe TERMIS-EU 2019 meeting is being held from the 27th to the 31st of May 2019 in Rhodes, Greece. The theme of the meeting is 'Tissue Engineering Therapies: From concept to clinical translation and commercialization'. The meeting is highly important to scientists, clinicians and industries interested in tissue engineering and regenerative medicine therapies that aspire to revolutionize healthcare with their reparative capacity.\nAbout CollPlant\nCollPlant is a regenerative medicine company focused on 3D bioprinting of tissues and organs, medical aesthetics, and on developing and commercializing tissue repair products for orthobiologics, and advanced wound care markets. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.\nOur products address indications for the diverse fields of organ and tissue repair, and are ushering in a new era in regene...